Cancer diagnosis marker using the aberrant glycosylation of a protein
AssigneeKorea Basic Science Institute
InventorsYeong Hee Ahn, Jong Shin Yoo
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for diagnosing cancer using information on the aberrant glycosylation of a glycoprotein. More precisely, the present invention relates to a cancer diagnosis peptide marker, which is screened by: a step of separating, using a lectin, a glycoprotein which is aberrantly glycosylated in accordance with the occurrence of cancer; and a step of selecting a hydrolyzed peptide marker derived from the aberrantly glycosylated glycoprotein by observing the quantitative changes in the separated glycoprotein. The present invention also relates to a method for diagnosing cancer using the peptide marker as an agent.
Claims9
1-18. (canceled)
A method for quantitative analysis of polypeptide to provide information for cancer diagnosis comprising the following steps:
- 1) separating and concentrating glycoproteins by treating a sample obtained from a subject with lectin;
- 2) hydrolyzing the glycoproteins of step 1) to obtain polypeptides;
- 3) quantitatively analyzing the polypeptides of step 2);
- and
- 4) diagnosing cancer or high risk of cancer when the subject has at least one of those polypeptides selected from the group consisting of those polypeptides having the molecular weights of 2294.1, 2015.0, 1685.8, 1346.7, 1265.7 and 1109.5 confirmed by the quantitative analysis of step 3).
A method for sequencing of polypeptide to provide information for cancer diagnosis comprising the following steps:
- 1) separating and concentrating glycoproteins by treating a sample obtained from a subject with lectin;
- 2) hydrolyzing the glycoproteins of step 1) to obtain polypeptides;
- 3) sequencing the polypeptides of step 2);
- and
- 4) diagnosing cancer or high risk of cancer when the subject has at least one of those polypeptides selected from the group consisting of those polypeptides having the amino acid sequences represented by SEQ. ID. NO:
- 1-NO:
- 6 confirmed by the sequencing of step 3).
A method for quantitative analysis and sequencing of polypeptide to provide information for cancer diagnosis comprising the following steps:
- 1) separating and concentrating glycoproteins by treating a sample obtained from a subject with lectin;
- 2) hydrolyzing the glycoproteins of step 1) to obtain polypeptides;
- 3) sequencing and quantitatively analyzing the polypeptides of step 2);
- and
- 4) diagnosing cancer or high risk of cancer when the subject has at least one of those polypeptides confirmed by the sequencing and quantitative analysis of step 3), wherein the polypeptide is selected from the group consisting of those polypeptides having the amino acid sequences represented by SEQ. ID. NO:
- 1-NO:
- 6 and selected from the group consisting of those polypeptides having the molecular weights of 2294.1, 2015.0, 1685.8, 1346.7, 1265.7 and 1109.5.
The method according to claim 1, wherein the sample of step 1) is the one characteristically selected from the group consisting of cell, cell culture fluid, blood, serum, and plasma.
The method according to claim 1, wherein the lectin of step 1) is the one or a combination of at least two of those characteristically selected from the group consisting of ConA, WGA, Jacalin, SNA, AAL, L-PHA, PNA, LCA, ABA, DBA, DSA, ECA, SBA, SSA, UEA, VVL, and BPL.
The method according to claim 1, wherein the hydrolysis of step 2) is performed by using one of enzymes characteristically selected from the group consisting of Arg-C, Asp-N, Glu-C, Lys-C, chymotrypsin, and trypsin.
The method according to claim 1, wherein an additional step of concentrating by using an antibody to the peptide of step 2) is characteristically included before the quantitative analysis of step 3).
The method according to claim 1, wherein the cancer is characteristically selected from the group consisting of colon cancer, liver cancer, stomach cancer, lung cancer, uterine cancer, breast cancer, prostatic cancer, thyroid cancer, and pancreatic cancer.
Dependencies are inferred from the claim text.